We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App




Seegene and Werfen to Jointly Develop Syndromic qPCR Assays

By LabMedica International staff writers
Posted on 15 Jun 2023

Seegene, Inc. More...

(Seoul, Korea) has entered into discussions with Werfen (Barcelona, Spain) to expand their ongoing collaboration within the Spanish and Portuguese markets through Seegene's OneSystem Business. Seegene and Werfen have a long-standing relationship, and the extended partnership will enable the co-development of syndromic qPCR assays suited for the healthcare systems of Spain and Portugal at Werfen's OEM Technology Center in Spain. These assays will include those for sexually transmitted infections and drug resistance.

The objective of Seegene's OneSystem Business is to share its syndromic quantitative PCR technologies and its SGDDS (digitalized development system). This system allows researchers, regardless of their experience level, to develop assays. Furthermore, Seegene aims to provide automated manufacturing technologies to create syndromic PCR assays compatible with its standardized OneSystem instruments. Through this partnership, Spain and Portugal will gain the knowledge and technology to develop and manufacture syndromic qPCR assays, thus creating an infrastructure capable of responding swiftly to future pandemics without depending on foreign products and resources.

Seegene's OneSystem Business is pursuing its ultimate goal of creating a world free from all diseases, including cancer and infectious diseases that affect not only humans but all organisms. To fulfill this objective, Seegene is building an open innovation global network where scientists worldwide can collaborate to develop syndromic quantitative PCR assays tailored to local needs. As part of this initiative, Seegene is actively looking for additional partners from other European countries to join its global network and anticipates further agreements to be concluded throughout the year to expedite the expansion of its OneSystem Business.

"We will share our PCR technologies and know-how with any company in any country wishing to develop syndromic quantitative PCR assays," said Dr. Jong-Yoon Chun, CEO of Seegene. "We aspire to develop PCR diagnostic assays for all diseases so that the world free from diseases would come closer."

"We are excited about the possibility of strengthening our partnership with Seegene, and we look forward to developing assays which are tailor-made for Spain and Portugal," said José Luis Zarroca, Chief Operating Officer, OEM at Werfen.

Related Links:
Seegene, Inc. 
Werfen 


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit
New
Shaking Incubator
Corning LSE 71L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more

Pathology

view channel
Image: The Aiforia Breast Cancer Grading AI solution is CE-IVD marked (Photo courtesy of Aiforia Technologies)

Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy

Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.